<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01038440</url>
  </required_header>
  <id_info>
    <org_study_id>PRV-09005</org_study_id>
    <nct_id>NCT01038440</nct_id>
  </id_info>
  <brief_title>Time and Dose Evaluation of Stearidonic Acid (SDA) to Eicosapentaenoic Acid (EPA) in Red Blood Cells</brief_title>
  <acronym>NK</acronym>
  <official_title>Evaluation of the Relationships of Time and Dose of Eicosapentaenoic Acid and Stearidonic Acid to the Changes in Eicosapentaenoic Acid Levels in Red Blood Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solae, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Provident Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Solae, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the relationships between dose and time of consumption
      of stearidonic acid (SDA) and eicosapentaenoic acid (EPA) on EPA enrichment of red blood cell
      (RBC) membranes in men and women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome variable will be the end of treatment EPA level in RBC membranes, expressed as a percent of total RBC membrane fatty acids.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome variables will include end of treatment values for: omega-3 Index (EPA + DHA as a percent of total RBC membrane fatty acids), triglycerides (TG), selected inflammatory markers</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Sudden Cardiac Death</condition>
  <condition>Sudden Cardiac Arrest</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EPA 0.5 g/d</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EPA 1.5 g/d</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EPA 3.0 g/d</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SDA 0.5 g/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SDA 1.5 g/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SDA 3.0 g/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SDA 6.0 g/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Safflower Oil</intervention_name>
    <description>One softgel consumed daily with food</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EPA</intervention_name>
    <description>Three different doses of EPA (0.5, 1.5 and 3.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.</description>
    <arm_group_label>EPA 0.5 g/d</arm_group_label>
    <arm_group_label>EPA 1.5 g/d</arm_group_label>
    <arm_group_label>EPA 3.0 g/d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>SDA</intervention_name>
    <description>Four different doses of SDA (0.5, 1.5, 3.0 and 6.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.</description>
    <arm_group_label>SDA 0.5 g/d</arm_group_label>
    <arm_group_label>SDA 1.5 g/d</arm_group_label>
    <arm_group_label>SDA 3.0 g/d</arm_group_label>
    <arm_group_label>SDA 6.0 g/d</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 21 to 65 years of age, inclusive.

          2. Body mass index (BMI) 18.00-39.99 kg/m2, at visit 1 (week -2).

          3. Subject is willing to avoid alcohol consumption for 24 hr prior to every clinic visit.

          4. The subject has no plans to change smoking habits during the study period.

          5. Subject is willing to maintain a stable body weight, current activity level, and
             dietary habits except for use of the study products as directed.

          6. Subject understands the study procedures and signs forms documenting informed consent
             to participate in the study and authorization for release of relevant protected health
             information to the study Investigator.

        Exclusion Criteria:

        1. Subject has coronary heart disease or a coronary heart disease risk equivalent including
        any of the following:

          -  Diabetes mellitus (or fasting glucose ≥126 mg/dL at visit 1).

          -  Clinical signs of atherosclerosis including peripheral arterial disease, abdominal
             aortic aneurysm, or certain types of carotid artery disease.

          -  Presence of multiple risk factors that give a person a greater than 20% chance for
             developing coronary artery disease within 10 years as determined by the Framingham
             risk index calculated at visit 1.

             2. Triglycerides ≥400 mg/dL at visit 1 (week -2). 3. If a smoker, subject smokes no
             more than 1 pack of cigarettes (20 cigarettes) per day.

             4. Abnormal laboratory test results of clinical importance, including, but not limited
             to, fasting creatinine ≥1.5 mg/dL, ALT or AST ≥1.5X the upper limit of normal or
             fasting glucose ≥126 mg/dL at visit 1.

             5. Uncontrolled hypertension, defined as resting systolic blood pressure ≥160 mm Hg or
             diastolic blood pressure ≥100 mm Hg at screening.

             6. Use of any lipid-altering drugs, including statins, bile acid sequestrants,
             cholesterol absorption inhibitors, fibrates, or prescription formulations of niacin
             within four weeks of visit 1 and throughout the study. 7. Use of EPA/DHA from a drug
             or supplement within four months of visit 1 and throughout the study period.

             8. Frequent use of any non-study-related EPA/DHA containing enriched foods (such as
             DHA-enriched eggs) within four months of visit 1 and throughout the study period.

             9. Use of flaxseed, perilla seed, hemp, spirulina, walnut, mustard seed or black
             currant oil for more than one week duration within four weeks of visit 1 .

             10. Consumption of fatty fish (salmon, herring, mackerel, albacore tuna, or sardines)
             more than twice per month within four months of visit 1 and throughout the study
             period.

             11. Use of any dietary supplement known to alter lipid metabolism. 12. Use of any
             weight-loss medication (prescription or over-the counter) within four weeks prior to
             visit 1 and throughout the study.

             13. Use of any weight loss supplement or program within four weeks of visit 1 and
             throughout the study.

             14. Females who are pregnant, planning to be pregnant during the study period,
             lactating, or women of childbearing potential who are unwilling to commit to the use
             of a medically approved form of contraception throughout the study period.

             15. History or presence of significant, renal, hepatic, gastrointestinal, pulmonary,
             biliary, neurological or endocrine disorders.

             16. History or presence of cancer, except for non-melanoma skin cancers . 17. Current
             or recent history of (within 12 months of visit 1, week -1) or strong potential for
             alcohol or substance abuse.

             18. Use of any investigational drug within 30 days prior to visit 1. 19. Individual
             has a condition the Investigator believes would interfere with his or her ability to
             provide informed consent, comply with the study protocol, which might confound the
             interpretation of the study results or put the person at undue risk.

             20. Medications and/or supplements known to influence lipid metabolism or body weight
             are not allowed within four weeks of visit 1. Unstable use of antihypertensive or
             thyroid medication will also not be permitted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ratna Mukherjea, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Solae, LLC</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/22064208</url>
    <description>Final Manuscript</description>
  </link>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2009</study_first_submitted>
  <study_first_submitted_qc>December 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2009</study_first_posted>
  <last_update_submitted>June 15, 2012</last_update_submitted>
  <last_update_submitted_qc>June 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Omega 3 fatty acids</keyword>
  <keyword>Omega 3 Index</keyword>
  <keyword>Stearidonic acid (SDA)</keyword>
  <keyword>Eicosapentaenoic acid (EPA)</keyword>
  <keyword>Red blood cells</keyword>
  <keyword>Lipids</keyword>
  <keyword>Inflammation markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Death</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

